Patents by Inventor Thomas Cavanak
Thomas Cavanak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7511014Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: GrantFiled: June 15, 2006Date of Patent: March 31, 2009Assignee: Novartis AGInventors: Thomas Cavanak, Ulrich Posanski
-
Publication number: 20070042943Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: ApplicationFiled: June 15, 2006Publication date: February 22, 2007Inventors: Thomas Cavanak, Ulrich Posanski
-
Patent number: 7081445Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: GrantFiled: March 1, 2004Date of Patent: July 25, 2006Assignee: Novartis AGInventors: Thomas Cavanak, Ulrich Posanski
-
Publication number: 20040167063Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: ApplicationFiled: March 1, 2004Publication date: August 26, 2004Inventors: Thomas Cavanak, Ulrich Posanski
-
Publication number: 20030060402Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: ApplicationFiled: September 4, 2002Publication date: March 27, 2003Inventors: Thomas Cavanak, Ulrich Posanski
-
Patent number: 6468968Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: GrantFiled: August 16, 2001Date of Patent: October 22, 2002Assignee: Novartis AGInventors: Thomas Cavanak, Ulrich Posanski
-
Publication number: 20020013272Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: ApplicationFiled: August 16, 2001Publication date: January 31, 2002Inventors: Thomas Cavanak, Ulrich Posanski
-
Patent number: 6306825Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: GrantFiled: April 19, 2000Date of Patent: October 23, 2001Assignee: Novartis AGInventor: Thomas Cavanak
-
Patent number: 6066616Abstract: The invention provides a pharmaceutical composition comprising a somatostatin analogue, and its use in the treatment of breast cancer. The pharmaceutical composition preferably contains lactic acid in addition to the somatostatin analogue and is better tolerated when administered by injection.Type: GrantFiled: February 11, 1998Date of Patent: May 23, 2000Assignee: Novartis AGInventors: Thomas Cavanak, Alan Harris
-
Patent number: 5977066Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: GrantFiled: March 24, 1998Date of Patent: November 2, 1999Assignee: Novartis AGInventor: Thomas Cavanak
-
Patent number: 5759997Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: GrantFiled: June 6, 1995Date of Patent: June 2, 1998Assignee: Novartis AGInventor: Thomas Cavanak
-
Patent number: 5759565Abstract: Pharmaceutical compositions for nasal administration comprising i) a calcitonin, and ii) benzalkonium chloride, and/or iv) a surfactant, suitable for application to the nasal mucosa, in iii) a liquid diluent or carrier, suitable for application to the nasal mucosa. The compositions are suitably adapted for administration in the form of a nasal spray.Type: GrantFiled: December 31, 1991Date of Patent: June 2, 1998Assignee: Novartis CorporationInventors: Moise Azria, Thomas Cavanak
-
Patent number: 5753618Abstract: The invention provides a pharmaceutical composition containing a somatostatin analogue, and its use in the treatment of breast cancer. The pharmaceutical composition preferably contains lactic acid in addition to the somatostatin analogue and is better tolerated when administered by injection.Type: GrantFiled: June 6, 1995Date of Patent: May 19, 1998Assignee: Novartis CorporationInventors: Thomas Cavanak, Alan Harris
-
Patent number: 5733569Abstract: Pharmaceutical compositions for nasal administration comprising i) a calcitonin, and ii) benzalkonium chloride, and/or iv) a surfactant, suitable for application to the nasal mucosa, in iii) a liquid diluent or carrier, suitable for application to the nasal mucosa. The compositions are suitably adapted for administration in the form of a nasal spray.Type: GrantFiled: June 6, 1995Date of Patent: March 31, 1998Assignee: Novartis CorporationInventors: Moise Azria, Thomas Cavanak
-
Patent number: 5652212Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: GrantFiled: June 6, 1995Date of Patent: July 29, 1997Inventors: Thomas Cavanak, Ulrich Posanski
-
Patent number: 5639724Abstract: Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10.Type: GrantFiled: December 6, 1993Date of Patent: June 17, 1997Assignee: Sandoz Ltd.Inventor: Thomas Cavanak
-
Patent number: 4758423Abstract: The present invention provides a nasal pharmaceutical composition comprising as active agent a compound of formula I, ##STR1## wherein R.sub.1 is hydrogen or halogen,R.sub.2 is hydrogen or alkyl of 1 to 4 carbon atoms,either (i) R.sub.3 is isopropyl, sec-butyl, or isobutyl, R.sub.4 methyl, ethyl or isopropyl and R.sub.5 hydrogen and R.sub.6 is hydrogen or methoxy or R.sub.5 and R.sub.6 are together a single bond,or (ii) R.sub.3 is benzyl, R.sub.4 is methyl, R.sub.5 is hydrogen and R.sub.6 is hydrogen or methoxy,in association with a pharmaceutically acceptable carrier or diluent, adapted for nasal or pulmonary administration.Type: GrantFiled: June 9, 1986Date of Patent: July 19, 1988Assignee: First Fidelity Bank, National Association, New JerseyInventors: Moise Azria, Thomas Cavanak
-
Patent number: 4654345Abstract: Lyophylisates comprising bromocriptine or an acid addition salt thereof capable of reconstitution in an isotonic vehicle to provide a stable formulation for occular instillation, useful e.g. in the treatment of glaucoma. Typical lyophylisates in accordance with the invention comprise: a lyophylisable acid, e.g. methane sulfonic acid, an acid addition salt of bromocriptine with said acid, e.g. bromocriptine mesylate, benzalkonium chloride and a lyophylisate matrix material.Type: GrantFiled: October 18, 1985Date of Patent: March 31, 1987Assignee: Sandoz Ltd.Inventor: Thomas Cavanak
-
Patent number: 4462983Abstract: The present invention provides a nasal or pulmonary pharmaceutical composition comprising as active agent a compound of formula I, ##STR1## wherein R.sub.1 is hydrogen or halogen,R.sub.2 is hydrogen or alkyl of 1 to 4 carbon atoms,either (i)R.sub.3 is isopropyl, sec-butyl, or isobutyl,R.sub.4 methyl, ethyl or isopropyl andR.sub.5 is hydrogen and R.sub.6 is hydrogen or methoxyor R.sub.5 and R.sub.6 are together a single bond,or (ii)R.sub.3 is benzyl, R.sub.4 is methyl, R.sub.5 is hydrogen and R.sub.6 is hydrogen or methoxy, or (III) dihydroergocristine,in association with a pharmaceutically acceptable carrier or diluent, adapted for nasal or pulmonary administration.Type: GrantFiled: December 8, 1981Date of Patent: July 31, 1984Assignee: Sandoz Ltd.Inventors: Moise Azria, Thomas Cavanak
-
Patent number: 4388307Abstract: The present invention provides a pharmaceutical composition comprising a pharmacologically active monocyclic peptide and a carrier comprising at least one of the following components:(a) a non-ionic ester of a triglyceride and a polyalkylene polyol,(b) a saturated fatty acid triglyceride, and(c) a mono- or di-glyceridehaving improved physical and absorption properties.Type: GrantFiled: February 9, 1982Date of Patent: June 14, 1983Assignee: Sandoz Ltd.Inventor: Thomas Cavanak